11:51 AM EST - Protox Therapeutics Inc. : announced publication of positive safety and efficacy results from the previously reported Phase 1 and 2 trials with PRX302 in men with moderate to severe BPH (benign prostatic hyperplasia). Senior author, Dr Sam Denmeade, together with his colleagues at Protox and Study Investigators, published the results in the Journal, European Urology. Protox Therapeutics Inc.
shares T.PRX are trading up $0.03 at $0.53.
